New hope for tough leukemia: drug combo aims to boost remission
NCT ID NCT07039877
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This study tests a new combination of drugs for people with acute lymphoblastic leukemia that has come back or not responded to treatment. The approach adds a low dose of venetoclax (a targeted drug) and itraconazole to a standard chemotherapy regimen called TACL. The goal is to improve the chance of achieving remission so patients can move on to a stem cell transplant. The trial enrolls 12 adults with Philadelphia chromosome-negative B-cell or T-cell leukemia.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBKASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Universitario Dr. Jose E. Gonzalez
RECRUITINGMonterrey, Nuevo León, 64360, Mexico
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.